Cardinal Health will implement Magnolia Medical Technologies’ Steripath sepsis-diagnosing device to hospitals both as a standalone product and as part of a customizable device kit that aims to address blood culture contamination.
The Steripath device isolates the patient’s blood portion that is most likely to contain contaminants and has presented up to 92 percent reduction in blood culture contamination, according to the news release.
With the device, Cardinal Health aims to decrease the impact of blood culture contamination on patient safety, quality outcome measures and healthcare costs.
More articles on health IT:
Deloitte, Change Healthcare join Amazon’s new data exchange service for the cloud
Google was about to post X-rays with personal data online before NIH stepped in
Intermountain CMIO: How interoperability bridges gaps in knowledge, decision support to improve patient care
